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Abstract: Bioisosteric replacements and scaffold hopping play an important role in modern drug discovery and design, as they enable the change 
of either a core scaffold or substitutes in a drug structure, thereby facilitating optimization of pharmacokinetic properties and patenting, while 
the drug retains its activity. A new knowledge-based method was developed to obtain bioisosteric or scaffold replacements based on the 
extensive data existing in the Protein Data Bank. The method uses all-against-all ProBiS-based protein superimposition to identify ligand 
fragments that overlap in similar binding sites and could therefore be considered as bioisosteric replacements. The method was demonstrated 
on a specific example of drug candidate – a nanomolar butyrylcholinesterase inhibitor, on which bioisosteric replacements of the three ring 
fragments were performed. The new molecule containing bioisosteric replacements was evaluated virtually using AutoDock Vina; a similar 
score for the original and the compound with replacements was obtained, suggesting that the newly designed bioisostere compound might 
retain the potency of the original inhibitor. 
 





HE concepts and methods of bioisosterism and 
scaffold hopping are becoming increasingly important 
in modern drug design.[1] The term bioisostere represents a 
functional group that can be used to replace another group 
in a drug molecule, while this new molecule retains the 
desired biological activity.[2] Bioisosteres are often used to 
replace a functional group that is important for binding to 
a target, but a new group in its place would: improve 
selectivity, lessen side effects, improve pharmacokinetics, 
increase metabolic stability, simplify synthetic route, or 
help avoid patent-related issues. Meanwhile, scaffold 
hopping can be considered a special type of bioisosteric 
replacement where the core structure of a small drug 
molecule is replaced.[3] The core structure may be of direct 
functional importance for interacting with the target 
protein or it may provide the necessary alternative 
scaffolding that allows for substitution with functional 
groups in the appropriate spatial arrangement. 
 While the concept of bioisosterism is relatively old, only 
recently have computational systematic and data-intensive 
methods been used to explore the appropriate replacements. 
These data mining approaches are becoming widespread, 
mostly due to the public availability of large structural 
databases of bioactive molecules and due to new efficient 
methods for identifying appropriate bioisosteric or scaffold 
replacements. BIOSTER, for example, is a database of compiled 
bioisosteric transformations obtained over the past forty years 
from literature.[4] ChEMBL (www.ebi.ac.uk/chembl/) is a 
public domain database of small molecules with associated 
bioactivity data that has been mined from the medicinal 
chemistry literature which contains over 1.5 million distinct 
compounds (release version 20).[5] Using ChEMBL, one can 
identify experimentally observed molecular transforms that 
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method is the Matched Molecular Pair (MMP) concept,[6] 
which is based on the identification of molecules in the 
ChEMBL that differ only in one functional group. This kind of 
identification allows for the analysis of potential changes in 
biological properties that may be affected by this 
transformation. The MMP concept implemented using the 
ChEMBL database has been made freely available on-line as 
the Swiss-Bioisostere database (www.swissbioisostere.ch).[7] 
Using this system one can quickly identify potential 
bioisosteric replacements for the query functional group. 
Other methods to identify bioisosteres based on mining the 
PDB ligands have also been described.[8–12] 
 In this work, we developed a unique knowledge-
based method to identify possible bioisosteric or scaffold 
hopping replacements for small molecules. We find bioiso-
steric replacements based on local binding site alignments 
using the ProBiS algorithm,[13–15] which enables finding 
bioisosterically replaceable fragments even in distantly 
related proteins. ProBiS superimposes binding sites and not 
entire protein structures (folds) nor protein sequences and 
seeks for locally similar spatial arrangements of physico-
chemically similar surface functional groups. It is therefore 
able to differentiate between binding pocket confor-
mations in proteins with similar overall sequence identity, 
as well as recognize similar binding pockets in proteins with 
very different sequences. This, we believe, is one of the 
main advantages of our method. In addition, to our 
knowledge, a rigorous method with clearly defined  
rules on how identified bioisosteric replacements should  
be connected to the original query structure does not 
exist yet. 
 The process of identification of possible bioisosteric 
replacements was started using the ProBiS algorithm,[13–15] 
with which we superimposed the holo protein structures 
from the Protein Data Bank (PDB) containing co-crystallized 
small ligands. We compared and aligned binding sites that 
contained co-crystallized ligands; we superimposed the 
binding sites that had similar three-dimensional amino acid 
residue arrangements. 
 The co-crystallized ligands were superimposed to-
gether with the binding sites, but were not used in the 
alignment procedure. Overlaps in the superimposed lig-
ands' molecular structures were then sought. The overlap-
ping ligands were fragmented to the basic elements of their 
structures, such as rings and various functional groups. The 
elements that had high spatial overlap measured by the 
Hausdorff distance were considered as bioisosterically 
replaceable. Thus, a database of about 14.000 possible 
bioisosteric replacements was created based on the  
PDB structural data that will benefit early stages of  
the drug development process. The collection of 
identified bioisosteric replacement pairs is available at 
http://insilab.org/files/bober/BoBER.zip. 
METHODS 
Binding Sites Data Preparation 
For binding sites database preparation we followed the 
same procedure as described previously.[16] In the follow-
ing, we briefly repeat the steps taken. 
 Step 1. For each protein chain (PDB/Chain identifier) 
in the April 2016 PDB release we constructed the biological 
assembly that contains this chain, based on the rules in the 
header of the corresponding PDB file. A biological assembly 
is the three-dimensional macromolecular assembly com-
posed of the protein chains that are or are believed to be the 
biological functional form. Next, we extracted the co-
crystallized ligands of the protein chain identified by HETATM 
from each biological assembly file; where we considered only 
ligands with > 7 heavy atoms, and at least one atom being  
< 3 Å from the particular protein chain. Non-specific binders 
and modified residues denoted by the MODRES code were 
discarded. The modified residues such as selenomethionines 
and glycosylation sites were discarded due to them not being 
true ligands; they are chemically modified amino acid 
residues that are part of the protein's chain. From each 
extracted ligand we then obtained its binding residues, i.e. 
protein atoms < 5 Å from any ligand atom, and generated the 
corresponding binding site surface files (.srf). 
 Step 2. We constructed an initial non-redundant pro-
tein single chain database using a sequence identity cutoff 
at 40 %. This was performed by clustering ~290.000 protein 
chains in the PDB by their sequence identity. Each resulting 
sequence cluster contained > 40 % sequence identical pro-
tein chains. In total, 27.148 clusters were obtained. From 
each of these clusters we then selected one protein chain 
with the lowest resolution as the representative chain, 
resulting in 27.148 unique protein chains. We then assigned 
each binding site obtained in Step 1 to its corresponding 
sequence cluster. 
 Step 3. Within each cluster obtained in Step 2, we 
compared each pair of binding sites (all against all) using 
ProBiS, and calculated their pairwise z-scores.[14] Then we 
clustered binding sites within each sequence identity clus-
ter and obtained around 11.000 binding site clusters. Each 
such binding site cluster contained from a few to many 
thousands of binding sites. 
 Step 4. For each binding site cluster we then super-
imposed all its member sites, their coordinates, together 
with their ligands onto the representative binding site, 
which is the largest binding site containing the ligand with 
most heavy atoms. To further reduce computational com-
plexity, the remaining protein chains were compared only 
to the top scored (z-score > 0) binding sites from their cor-
responding cluster representative. Thus we obtained the 
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 Step 5. Using the ProBiS algorithm, we compared 
each existing protein structural chain in the PDB with the 
binding site surfaces obtained in Step 4. There are  
> 290.000 protein chains in the PDB so to facilitate this task, 
we took the approximately 44.000 representatives of 90 % 
sequence identity clusters (obtained by the same 
procedure as in Step 2) and compared each against the 
binding site surfaces from Step 4. To further reduce 
computational complexity, the remaining protein chains 
were compared only to the top scored (z-score > 0) binding 
sites from their corresponding cluster representative. This 
allowed us to get accurate predictions for each protein 
chain in the PDB at a lower computational cost comped to 
if we considered all of the protein chains. Finally, only 
similar binding sites with z-score > 2.5 were considered 
further. From the obtained alignments for each protein 
chain, we obtained possible overlapping ligands that could 
be used as potential bioisosteric replacements. When a 
ligand is at the interface of two protein chains, it will be 
considered twice – one time for each chain. 
Fragmenting of Overlapped Ligands 
After binding site superimposition, all of the ligands were 
fragmented using an “in-house” developed C++ program to 
obtain smaller fragment-like structures which should be 
suitable as bioisosteric replacement groups. The program 
works by identifying all the rotatable bonds within a 
molecule. The molecule is then broken along these bonds, 
and all bond atoms are proclaimed as “join” atoms; all 
other atoms are “core” atoms. Finally, atom types for every 
atom in each fragment are determined using the IDATM 
algorithm as implemented in the UCSF Chimera.[17] 
Fragments that are not interesting as bioisosteric 
replacements, that is, fragments containing less than four 
heavy atoms and fragments lacking at least one atom that 
could act as a hydrogen bond donor or acceptor, are not 
considered further. 
 As reconnecting the newly obtained fragments to 
the original structure is not trivial, rigorous atom typing of 
join atoms is essential to determine how to reconnect the 
bioisosteres in a new molecule. Atom typing also decides if 
the reconnection is possible at all. 
Rules for Bioisosteric Replacements 
We defined new rules for join atom replacements to 
expand the search space of possible bioisosteric 
replacements for each original fragment. These rules 
ensure that bioisosteres can be found for most fragments 
making the approach widely applicable: 
 Rule 1. Join atoms in the bioisosteric fragment can 
be replaced with atoms having similar hybridization 
properties. For example, see fragments 3 and 5 in Table 1, 
in which N.pl atom types were replaced with C.sp2 as in the 
reference fragment (Figure 1, upper left and Figure 5). 
 Rule 2. If a bioisosteric fragment has more join atoms 
than the reference fragment, then only those join atoms 
from the bioisosteric fragment that are bound to core 
atoms that overlap join-atom-binding core atoms of the 
reference fragment are considered; others are ignored, for 
example in fragments 2 and 4 in Table 1 we ignore C.ar 
atoms; in 5 we ignore the C.sp3 atom (Figure 1, upper 
right). 
 Rule 3. If we do not obtain any bioisostere 
replacements due to the uniqueness of the reference 
fragment, then the structure of this fragment is reduced by 
removing some join atoms. A smaller and usually less 
unique fragment is thus obtained. 
 Rule 4. If the bioisosteric fragment has less join 
atoms than the reference fragment, then join atoms on the 
bioisosteric fragment are created. A join atom is added to 
the core atom of the bioisosteric fragment that is the 
closest to the overlapped core atom of the reference 
fragment bound to a join atom. The new join atom on the 
bioisosteric fragment is assigned the atom-type of the 
original join atom on the reference fragment based on 
which it was created. 
 Rule 5. One or more of the above rules can be 
applied in sequence. A special case is the combination of 
Rule 3 and Rule 4 (Figure 1, lower half). By applying Rule 
3, we remove join atoms that are required by Rule 4 in 
order to add join atoms to the discovered bioisosteric 
fragments. This problem is solved by reconnecting join 
atoms to the reduced reference fragment in the same way 
as they were in the original fragment after the completion 
of database screening (Figure 1, lower half, step 2). Rule 
4 can then be used. Examples of fragments obtained by 
first applying Rule 3 and then Rule 4 are fragments 6–9 in 
Table 2. 
Fragment Overlap Evaluation via 
Hausdorff Distance 
To assess the appropriateness of a certain fragment as a 
bioisostere, we determined its spatial overlap with the 
reference fragment using the Hausdorff distance (HD) as a 
measure of molecular overlap.[18] Such “molecular” HD is a 
very fast and effective way to measure the similarity 
between a pair of candidate fragments. The HD is defined 
as the greatest of all the distances from a point in one set 
to the closest point in the other set (Figure 2). 
 We calculated the molecular HD between the 
candidate bioisostere and reference fragments based on 
the overlapping points of their van der Walls surfaces. The 
fragment pairs having HD < 1.5 Å were considered as 
bioisosterically replaceable. The overall procedure is 
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RESULTS AND DISCUSSION 
Bioisosteric replacements are commonly used in drug 
design to alleviate unwanted properties of drugs such as 
low solubility, low bioavailability, or high toxicity. Using our 
approach, we obtained 14.407 potential bioisosteric 
replacements. To assess the structural diversity of these 
bioisosteric pairs, we measured the Tanimoto coefficient of 
each individual pair using the OpenBabel's FT4 method.19 
The average Tanimoto coefficient was ~0.5 ± 0.3; thus, on 
average the structures of the bioisosteric replacement pairs 
differ significantly. 
 To demonstrate the usefulness of our approach,  
we applied it to a previously published nanomolar 
butyrylcholinesterase inhibitor[20] (PDB code: 3F9) serving 
as a reference compound (Figure 4, upper half). First, the 
inhibitor structure was fragmented, enabling recognition of 
its basic structural elements. Then, possible bioisosteric 
replacements for the existing fragments in the reference 
molecule were identified. As rings are often the most 
promising for bioisosteric replacements, the search was 
focused on the three rings found in this compound, that is 
the naphthalenyl, the piperidinyl and the dihydroindenyl 
rings (Figure 4, lower half). 
 
Figure 1. Rules for bioisosteric replacements. Rule 1: N.pl
join atom (red circle) is replaced by C.sp2 join atom (green 
circle), having the same hybridization state, to enable 
connection of the new bioisosteric fragment (blue) with the 
rest of the compound structure (shown in Figure 5). Rule 2: 
reference fragment (orange) and the bioisosteric 
replacement fragment (blue) overlap due to the alignment 
of their co-crystallized binding sites. The C.sp3 join atom in 
the bioisosteric fragment (red circle) is removed as there is 
no corresponding overlapping atom in the reference 
structure. The bioisostere N.sp2 join atom is overlapped 
with the reference C.sp2, thus considered further (green 
circle). Rule 3: to reduce the uniqueness of the reference 
fragment the N.pl join atom is removed (red circle). Then, 
database screening is initiated and overlapping bioisosteric 
structures are found (blue). Then, Rule 4 cannot be used, as 
we have no join atoms on the reference (orange) structure 
(green circle). Therefore, we reconnect the original N.pl join 
atom to the reference fragment (green circle). Rule 4: the 
N.pl join atom is created on the bioisosteric fragment as a 
copy of the reference join atom (green circle). 
 
 
Figure 2. Molecular Hausdorff distance calculation. One-
sided (oHD) distances are calculated for overlapping 
molecules A and B. oHD(A, B) is the minimum distance 
between a surface point of an atom in molecule A that is the 
furthest from any surface point in molecule B, and a surface 
point of atoms in molecule B; the oHD(B, A) is calculated 
using reversed rules. The molecular HD(A,B) is the larger of 
the two oHDs, i.e., the oHD(A,B) (bold). 
Figure 3. Overview of the bioisosteric replacement 
generation approach. (1) Using ProBiS, protein structures 
(cyan and orange ribbons) are superimposed based on their 
local binding site (red arrow) similarity; (2) The co-
crystallized ligands (blue and orange sticks) are rotated and 
translated based on the superimposition matrices acquired 
from the protein binding sites superimposition; (3) Ligands 
are fragmented and the HD between pairs of overlapped 
fragments originating from different ligands are calculated;
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 For the naphthalenyl moiety we considered the 
fragments as bioisosterically replaceable if their HD < 1.0 Å. 
We found five non-trivial cyclic fragments (Table 1) that 
also contained the appropriately hybridized join atom 
(C.sp2 or N.pl) – meaning that the fragments can be 
connected to the main structure in a similar way as in the 
original reference fragment, and thus retaining an 
appropriate chemical environment. In fragments 3 and 5 
the connecting join atom is N.pl, which would lead to a 
structure containing an improbable N=O–N group. 
Therefore, we replaced this join atom according to Rule 1 
(see Methods) with C.sp2 atom, to obtain a more probable 
structure (Figure 5). Further, based on Rule 2, we have 
retained the N.pl join atom in fragment 5, while ignoring 
the C.sp2 join atom. We did this because the core atom that 
binds the C.sp2 join atom in the bioisosteric fragment does 
not overlap with any join-binding core atom from the 
reference fragment (Figure 1, upper right). 
 For the dihydroindenyl moiety as the reference 
fragment (Figure 4, right) we could not find any possible 
bioisosteric replacements; however, if we excluded the 
N.sp3 join atom using Rule 3 (see Methods) and used this 
reduced fragment without the join atom to scan the 
database, we were able to obtain potential bioisosteric 
replacements (Table 2). These exhibited low HDs towards 
the reference fragment. As fragments 6-9 did not contain 
any join atoms, we added them based on the spatial 
overlapping of the reference and bioisosteric core atoms 
that are bound to the join atoms in the original structure 
(Rules 4 and 5 and Figure 1, lower half). 
 Finally, we repeated the same procedure for the 
piperidinly fragment without the C.sp3 join atom bound to 
the core carbon, since using the exact same moiety (Figure 
4, middle) we did not obtain any overlapping fragments 
with low HDs. Observing many examples of overlapping 
fragments, we found empirically that HD of 1.5 Å is most 
likely the uttermost limit at which the fragments are still 
suitable for bioisosteric replacement. Here, the lowest 
scoring fragment when using the original structure was 
over 2.0 Å. Consequently, we used a simpler structure 
containing only core atoms of the piperidinly moiety (Rule 
3). With this procedure we obtained possible bioisostereic 
fragments, which are shown in Table 3. Similarly as in the 
previous example, one of the join atoms in every fragment 
11–15 was added based on the spatial overlap of the 
reference and bioisosteric core atoms that were bound to 
the join atoms in the original structure (explained in Figure 
1, lower half and by Rules 4 and 5). 
 To further test our bioisostere replacement 
approach for scaffold hopping, we built a new molecule 
(Figure 6) in which all of the rings of the 3F9 structure were 
replaced with their best predicted bioisosteric pair based 
on HD (fragments 1, 6, and 11). This new molecule was then 
aligned to the reference compound in the binding site of  
 
Figure 4. The structure of the butyrylcholinesterase inhibitor 
(PDB code 3F9) (above) and the structures of the three ring 
fragments obtained (below). Some fragments have 
overlapping atoms (join atoms); e.g., the same nitrogen 
atom (red asterisk) is present in both the piperidinyl and 
dihydroindenyl fragment. The hybridization states of join 
atoms are explicitly shown, i.e., C.sp2, C.sp3, and N.sp3. 
 
 
Figure 5. A new bioisosteric derivative of compound 3F9 
with the naphthalenyl moiety replaced by benzothiazo-
laminyl fragment 3 from Table 1; the N.pl join atom 
suggested by original bioisosteric replacement fragment 
was replaced according to Rule 1 with an C.sp2 atom for 
chemical feasibility. 
 
Figure 6. A molecule obtained by performing bioisosteric 
replacements of all rings in the 3F9 ligand. The fragments 
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Table 2. Five best examples (compounds 6–10) by HD of 
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Table 1. Five best examples (compounds 1–5) by HD of 
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Table 3. Five best examples (compounds 11–15) by HD of 
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Figure 7. Bioisosteric structure (orange) generated with our 
approach overlapped with the original inhibitor 3F9 (blue) 
in the butyrylcholinesterase binding site (green). A good 
overlap between the structures important for binding 
(hetero atoms and cyclic fragments) is observed. Based on 
AutoDock Vina scoring function the binding energy of the 
3F9 ligand is –9.7, while for the new potential inhibitor it is 
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the butyrylcholinesterase using ChemAxon MarvinSketch[21] 
three-dimensional alignment tool. The new molecule was 
further manually optimized to better the alignment (Figure 7). 
To evaluate the binding energy of the original 3F9 structure 
and of our bioisostere structure, we used the AutoDock 
Vina[22] score only function. The binding energy obtained 
for the original structure was –9.7 kcal/mol, while for the 
bioisosteric structure it was –8.4 kcal mol–1, which is within 
the standard error of 2.8 kcal mol–1 for AutoDock Vina.[22] 
Based on this result, we can therefore predict that the 
binding energy of our new ligand might be similar to that of 
the original co-crystallized ligand. 
 
CONCLUSION 
We developed a knowledge-based method that uses binding 
sites superposition to identify possible bioisosteric and 
scaffold hopping replacements for existing inhibitors. The 
novel predicted bioisosteric replacements were obtained 
from existing crystal structures of ligands in the PDB, which 
makes us confident that the newly obtained compounds will 
retain the activity. A major difficulty was to decide how the 
join atoms should be considered. Join atoms that are a part 
of reference fragments can make some fragments, despite 
the large size of the PDB database, unique, and in such cases 
no suitable bioisosteric replacements can be obtained. Thus 
to expand the possibility of finding good replacements, we 
defined five rules that can be used for this purpose. Another 
problem with the structures obtained is the possible 
synthetic inaccessibility of these compounds. However, 
methods exist that can check the theoretically built structure 
for synthetic accessibility;[23] therefore we can still screen out 
compounds which could not be efficiently synthesized, thus 
focusing on accessible compounds in further experimental 
studies. We showed a use case of our new method on the 
example of butyrylcholinesterase inhibitors. The generated 
bioisostere compound had the predicted energy of binding 
almost equal to that of the reference butyrylcholinesterase 
inhibitor. A definite confirmation of the usefulness of this 
method will come from experimental studies, which are 
planned in the future. It is also our plan to implement this 
method in LiSiCA,[24] our ligand-based virtual screening 
software, to enable searching large databases for similar 
ligands not only on the basis of atom type similarity but also 
based on possible bioisosteric or scaffold hopping 
replacements. 
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